SecBot SecBot
SECBOTREPLAY Home › Report › CRBU

CRBU · Caribou Biosciences announced long-term follow-up data from its ANTLER…

Caribou Biosciences, Inc. · 8-K filed Jun 11, 2026 at 08:02 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jun 11, 2026 at 08:02 ET

Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage phase 1 (CB-011, anti-BCMA) trials at the EHA 2026 meeting. For vispa-cel in 2L LBCL (pivotal subgroup, N=27): 82% ORR, 67% CR, 17.1-month mPFS. For CB-011 in r/r MM (BCMA-naïve RDE cohort, N=12): 92% ORR, 83% CR, 91% MRD negativity. Both assets showed manageable safety profiles. The company also reiterated FDA alignment on the design of the ANTLER-3 pivotal phase 3 trial for vispa-cel. This data update is a notable but incremental catalyst for this pre-revenue clinical-stage biotech, positive efficacy readouts but from small, single-arm cohorts without financial guidance.

  • Vispa-cel in 2L LBCL (pivotal optimized subgroup, N=27): 82% ORR, 67% CR rate, 17.1-month median PFS
  • CB-011 in BCMA-naïve r/r MM at RDE (N=12): 92% ORR, 83% CR rate, 91% MRD negativity in 10/11 evaluable, 50% in CR at 15 months
  • CB-011 case study: 71-yo male with 8 prior lines (including autologous CAR-T) achieved CR at day 28, ongoing
  • No GvHD or Gr≥3 ICANS in both pivotal optimized vispa-cel subgroup (N=27) and CB-011 RDE cohort (N=12)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access